Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

1.

Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels.

Mahal K, Resch M, Ficner R, Schobert R, Biersack B, Mueller T.

ChemMedChem. 2014 Apr;9(4):847-54. doi: 10.1002/cmdc.201300531. Epub 2014 Feb 23.

PMID:
24678059
[PubMed - indexed for MEDLINE]
2.

Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.

Conconi MT, Marzaro G, Urbani L, Zanusso I, Di Liddo R, Castagliuolo I, Brun P, Tonus F, Ferrarese A, Guiotto A, Chilin A.

Eur J Med Chem. 2013 Sep;67:373-83. doi: 10.1016/j.ejmech.2013.06.057. Epub 2013 Jul 6.

PMID:
23900004
[PubMed - indexed for MEDLINE]
3.

Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.

Ravez S, Barczyk A, Six P, Cagnon A, Garofalo A, Goossens L, Depreux P.

Eur J Med Chem. 2014 May 22;79:369-81. doi: 10.1016/j.ejmech.2014.04.007. Epub 2014 Apr 5.

PMID:
24747748
[PubMed - indexed for MEDLINE]
4.

MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.

Kasibhatla S, Baichwal V, Cai SX, Roth B, Skvortsova I, Skvortsov S, Lukas P, English NM, Sirisoma N, Drewe J, Pervin A, Tseng B, Carlson RO, Pleiman CM.

Cancer Res. 2007 Jun 15;67(12):5865-71.

PMID:
17575155
[PubMed - indexed for MEDLINE]
Free Article
5.

The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo.

Burns CJ, Fantino E, Powell AK, Shnyder SD, Cooper PA, Nelson S, Christophi C, Malcontenti-Wilson C, Dubljevic V, Harte MF, Joffe M, Phillips ID, Segal D, Wilks AF, Smith GD.

J Pharmacol Exp Ther. 2011 Dec;339(3):799-806. doi: 10.1124/jpet.111.186965. Epub 2011 Sep 14.

PMID:
21917561
[PubMed - indexed for MEDLINE]
Free Article
6.

4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model.

Schobert R, Biersack B, Dietrich A, Effenberger K, Knauer S, Mueller T.

J Med Chem. 2010 Sep 23;53(18):6595-602. doi: 10.1021/jm100345r.

PMID:
20731355
[PubMed - indexed for MEDLINE]
7.

Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents.

Wang G, Li C, He L, Lei K, Wang F, Pu Y, Yang Z, Cao D, Ma L, Chen J, Sang Y, Liang X, Xiang M, Peng A, Wei Y, Chen L.

Bioorg Med Chem. 2014 Apr 1;22(7):2060-79. doi: 10.1016/j.bmc.2014.02.028. Epub 2014 Mar 1.

PMID:
24629450
[PubMed - indexed for MEDLINE]
8.

Synthesis and antiproliferative activity of 4-substituted-piperazine-1-carbodithioate derivatives of 2,4-diaminoquinazoline.

Cao SL, Han Y, Yuan CZ, Wang Y, Xiahou ZK, Liao J, Gao RT, Mao BB, Zhao BL, Li ZF, Xu X.

Eur J Med Chem. 2013 Jun;64:401-9. doi: 10.1016/j.ejmech.2013.04.017. Epub 2013 Apr 15.

PMID:
23665106
[PubMed - indexed for MEDLINE]
9.

Quinazoline-sulfonamides as potential antitumor agents: synthesis and biological testing.

Alafeefy AM, Alqasoumi SI, Ashour AE, Alshebly MM.

J Enzyme Inhib Med Chem. 2013 Apr;28(2):375-83. doi: 10.3109/14756366.2012.668541. Epub 2012 Apr 2.

PMID:
22468752
[PubMed - indexed for MEDLINE]
10.

Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects.

Jiang Z, Wu M, Miao J, Duan H, Zhang S, Chen M, Sun L, Wang Y, Zhang X, Zhu X, Zhang L.

Int J Biochem Cell Biol. 2013 Aug;45(8):1710-9. doi: 10.1016/j.biocel.2013.04.030. Epub 2013 May 20.

PMID:
23702033
[PubMed - indexed for MEDLINE]
11.

Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.

Rao GW, Xu GJ, Wang J, Jiang XL, Li HB.

ChemMedChem. 2013 Jun;8(6):928-33. doi: 10.1002/cmdc.201300120. Epub 2013 May 2.

PMID:
23640754
[PubMed - indexed for MEDLINE]
12.

Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.

Zhang GM, Zhang YM, Fu SB, Liu XH, Fu X, Yu Y, Zhang ZY.

Chin Med J (Engl). 2008 Nov 20;121(22):2324-30.

PMID:
19080341
[PubMed - indexed for MEDLINE]
13.

Effects of the novel vascular targeting agent MDS-11P on tumor vascularity and its antitumor activity.

Deng ZT, Feng T, Wang P, Qi X, Chen XH, Li YX, Song CL, Geng MY, Li J.

Biochem Pharmacol. 2011 Dec 15;82(12):1832-42. doi: 10.1016/j.bcp.2011.08.024. Epub 2011 Sep 6.

PMID:
21920350
[PubMed - indexed for MEDLINE]
14.

Gold(I) biscarbene complexes derived from vascular-disrupting combretastatin A-4 address different targets and show antimetastatic potential.

Muenzner JK, Biersack B, Kalie H, Andronache IC, Kaps L, Schuppan D, Sasse F, Schobert R.

ChemMedChem. 2014 Jun;9(6):1195-204. doi: 10.1002/cmdc.201400049. Epub 2014 Mar 19.

PMID:
24648184
[PubMed - indexed for MEDLINE]
15.

Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.

Daenen LG, Shaked Y, Man S, Xu P, Voest EE, Hoffman RM, Chaplin DJ, Kerbel RS.

Mol Cancer Ther. 2009 Oct;8(10):2872-81. doi: 10.1158/1535-7163.MCT-09-0583.

PMID:
19825805
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Design, synthesis and biological evaluation of 2-mercapto-3-phenethylquinazoline bearing anilide fragments as potential antitumor agents: molecular docking study.

Al-Suwaidan IA, Alanazi AM, Abdel-Aziz AA, Mohamed MA, El-Azab AS.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3935-41. doi: 10.1016/j.bmcl.2013.04.056. Epub 2013 Apr 29.

PMID:
23683592
[PubMed - indexed for MEDLINE]
17.

YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.

Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Hisamichi H, Matsuhisa A, Shirasuna K, Kudoh M, Shibasaki M.

Clin Cancer Res. 2006 Mar 1;12(5):1630-8.

PMID:
16533791
[PubMed - indexed for MEDLINE]
Free Article
18.

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF.

Cancer Res. 2002 Aug 15;62(16):4645-55.

PMID:
12183421
[PubMed - indexed for MEDLINE]
Free Article
19.

Design and synthesis of novel quinazoline nitrogen mustard derivatives as potential therapeutic agents for cancer.

Li S, Wang X, He Y, Zhao M, Chen Y, Xu J, Feng M, Chang J, Ning H, Qi C.

Eur J Med Chem. 2013 Sep;67:293-301. doi: 10.1016/j.ejmech.2013.06.055. Epub 2013 Jul 4.

PMID:
23871909
[PubMed - indexed for MEDLINE]
20.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

PMID:
14522925
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk